17,261 trials
Papillomavirus Infections · Genital Diseases, Female
Primary: Number of Subjects With Injection Site Adverse Experiences — 247; 248; 266; 107 Participants
Osteoporosis
Primary: Change in Marker of Bone Metabolism, PINP — -13.1; 20.0; 90.8; 97.2 Percent change from baseline — p=<0.001
Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Summary of Adverse Events (AEs) — 9; 13; 7; 12 participants
Low Bone Mineral Density
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms — -0.81; 4.41; 4.71; 6.69 Percent change — p=<0.001
Benign Prostatic Hyperplasia
Primary: Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint — -4.5; -4.9; -3.8 units on a scale — p=0.201
Breast Cancer
Primary: Overall Response Rate (ORR) — 0.489; 0.587 proportion of responders — p=0.117
Hearing Loss
Primary: Temporary Threshold Shift Measurement by Pure Tone Audiometry (A Total of Four Hearing Assessments Were Completed for Each Formulation Period on the 1st Day Pre- and…
Breast Cancer
Primary: Number of Patients With Pathological Complete Response (Pathological Complete Response Rate) — 13 participants
Stroke · Dysphagia
Primary: Change in Duration of Superior Hyolaryngeal Movement — .213; .233 seconds
Influenza
Primary: Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen — 14.7; 27.9; 6.7; 13.6 Titer
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Overall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant — 7; 6; 1; 12 participants
Non-small Cell Lung Cancer · Mesothelioma · Lung Neoplasms
Primary: Overview of Adverse Events — 28; 23; 12; 1 participants
Beta Haemolytic Streptococcal Infection
Primary: The Time to First Vaginal Swab That is Type III GBS Culture Positive, With All Previous Cultures Negative for Type III GBS, Not Just the Immediately Preceding Culture…
Diabetic Foot Ulcer · Amputation
Primary: Number of Participants With Limb Salvage — 37; 31 Participants
HPV Infections
Primary: Combined Incidence of Persistent Human Papillomavirus (HPV) 6, 11, 16 and 18 Infection or HPV 6, 11, 16 and 18 Related-Disease as Determined by Clinical/Pathologic…